NexImmune, Inc.: restructuring charge — NexImmune pivots to AIM INJ platform, cuts workforce 30%, pauses two cell therapy trials

NexImmune, Inc.

Strategic shift: focus on AIM INJ 'off-the-shelf' platform; pause NEXI-001 AML and NEXI-003 HPV trials, seek external partners.
Workforce reduction from 74 to ~50 employees; approx $0.7M severance costs expected in Q4 2022.
Cash $45.9M as of Sep 30, 2022 (down from $53.1M June 30); cash runway extended to Q3 2023 via restructuring.
Q3 2022 net loss $14.7M ($0.60 loss per share) vs $14.6M ($0.65) prior year; R&D $11.1M, G&A $3.7M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NexImmune, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or, EPS $0.60.

Period: the third quarter ended September 30, 2022
Net income: Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or
EPS: $0.60
Result: reported results

Exact text from the filing

Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or a basic and diluted GAAP loss per share of $0.60.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

NexImmune, Inc. announced a restructuring with charges of approximately $0.7 million affecting Company (reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ).

Type: restructuring
Charge: approximately $0.7 million
Affected area: Company
Headcount: reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ

Exact text from the filing

On November 14, 2022 , NexImmune, Inc. (the “Company”) announced that, following a strategic review of its pipeline, indications, timelines and cash position, its Board of Directors approved and its management is implementing a strategic realignment initiative and corresponding reduction in workforce, designed to reduce costs and reallocate resources towards its preclinical development programs based on its proprietary Artificial Immune Modulation, or AIM TM , technology. The realignment would reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employees. The Company estimates that it will incur approximately $0.7 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0001538210-22-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.